106 Results
Sort By:
Published on September 22, 2023
A team of researchers from the Universities of Geneva (UNIGE), Lausanne (UNIL), the Geneva University Hospitals (HUG) and the Vaud University Hospital (CHUV) in Switzerland have discovered how to prolong the functionality of CAR-T cells by inhibiting a specific metabolic mechanism. CAR-T cell immunotherapy, which involves taking immune cells from…
Published on January 3, 2022
Scientists have developed a new type of CAR-T cells that act as a “micropharmacy.” The cells co-express bacterial enzymes that activate prodrugs at the disease site, killing both tumor cells that contain the cancer marker as well as nearby cancer cells that do not. What’s more, the engineered cells can…
Published on July 22, 2021
Researchers at La Jolla Institute for Immunology (LJI) have discovered how to prevent T-cell exhaustion, which they hope will make CAR T-cell cancer therapies more effective. The newly reported findings demonstrate the key role of the transcription factor BATF in the cellular pathway that triggers T cell exhaustion, and show…
Published on October 22, 2024
Research led by teams in Lausanne, Switzerland has developed a chimeric antigen-receptor (CAR)-T cell therapy that can be switched on and off using readily available existing drugs. CAR-T cell therapies are a type of cancer immunotherapy where T cells are engineered to better target the cancer cells of interest. These…
Published on October 9, 2024
Researchers from the University of California, Los Angeles (UCLA) have unveiled a new tool consisting of graphene oxide with attached antibodies that allows engineered CAR-T cells to more closely mimic the natural interactions between immune cells, effectively boosting the therapy’s cancer-fighting attributes. This innovation, reported recently in the journal Nature…
Published on September 19, 2024
Hematologist oncologist Miloš Miljković, MD, joined Cartesian Therapeutics as chief medical officer (CMO) in September 2021 from the National Cancer Institute (NCI) to do what he does best—develop and execute clinical programs—to help the RNA cell therapy company re-establish its stride in autoimmunity following the COVID-19 pandemic. “CAR-Ts have become…
Published on July 24, 2024
A research study led by the University of Kansas suggests that the FDA-mandated monitoring period of diffuse large B-cell non-Hodgkin lymphoma patients receiving chimeric antigen receptor (CAR)-T cell therapy could be halved without harm to patients. Writing in the journal Blood Advances, first author Nausheen Ahmed, a researcher and hematologist…
Published on July 15, 2024
A phase I clinical trial at Stanford Medicine has found that a new CAR-T cell therapy that targets a different protein—CD22—from the original therapy significantly improved patients’ outcomes. Over half of 38 people enrolled in the trial—37 of whom had already relapsed from the original CAR-T therapy—experienced a complete response…
Published on May 29, 2024
Researchers at the University College London (UCL) and UCL Great Ormond Street Institute of Child Health have developed a novel immunotherapeutic platform technology that uses engineered T cells to attack bone cancer cells and activate other cancer-fighting immune cells to do the same. The researchers aimed to overcome different challenges…
Published on May 8, 2024
A team of researchers at the Montefiore Einstein Comprehensive Cancer Center (MECCC) have demonstrated that altering two of the four key proteins in chimeric antigen receptors (CARs) improved their ability to attack and shrink glioblastoma, pancreatic, and lung tumors in mouse models of these cancers. The new approach, reported in…
Published on February 7, 2024
A new study uncovers why natural killer (NK) cells stop actively attacking tumor cells once they infiltrate cancers and possibly offers a way to boost their activity. The researchers, from the University of Birmingham and the University of Cambridge, found evidence of why NK cells adopt a dormant state when…
Published on February 7, 2024
Researchers from Northwestern University and the University of California, San Francisco (UCSF), reporting Wednesday in the journal Nature, say they have developed a new technique to encode human T cells with a mutation found in malignant T cells that cause lymphoma. The investigators say this new immunotherapy approach is 100…
Published on January 3, 2024
In what could be a big step forward for immunotherapy, ”unprecedented NK [natural killer] cell-engaging Nanodrones” that can selectively target specific cancer cells have been developed, by researchers at Ulsan National Institute of Science and Technology (UNIST). This approach, the researchers suggest, could be used to address types of cancers…
Published on December 27, 2023
AstraZeneca is acquiring cell therapy developer Gracell Biotechnologies Inc. for $1.2B. Gracell is focused on cancer and autoimmune diseases and, importantly, has a toehold in China. The biotech has ten programs in preclinical or later phases. Its most advanced candidate, GC012F, is in Phase I/II trials in the U.S. and…
Published on August 21, 2023
Moderna will partner with Chinese biotech CARsgen to co-develop a combined CAR T-cell and mRNA cancer vaccine therapy. The collaboration aims to combine Moderna’s Claudin18.2 mRNA cancer vaccine with CARsgen’s investigational Claudin18.2 autologous CAR T-cell product candidate (CT041) to test efficacy for targeting hard to treat cancers. Claudin 18.2 is…